Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis - PubMed (original) (raw)
. 1999 May 1;162(9):5511-8.
Affiliations
- PMID: 10228032
Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis
M P Keane et al. J Immunol. 1999.
Abstract
Few studies have addressed the importance of vascular remodeling in the lung during the development of bleomycin-induced pulmonary fibrosis. For fibroplasia and deposition of extracellular matrix to occur, there must be a geometric increase in neovascularization. We hypothesized that net angiogenesis during the pathogenesis of fibroplasia and deposition of extracellular matrix during bleomycin-induced pulmonary fibrosis are dependent in part upon an overexpression of the angiogenic CXC chemokine, macrophage inflammatory protein-2 (MIP-2). To test this hypothesis, we measured MIP-2 by specific ELISA in whole lung homogenates in either bleomycin-treated or control CBA/J mice and correlated these levels with lung hydroxyproline. We found that lung tissue from mice treated with bleomycin, compared with that from saline-treated controls, demonstrated a significant increase in the presence of MIP-2 that was correlated to a greater angiogenic response and total lung hydroxyproline content. Neutralizing anti-MIP-2 Abs inhibited the angiogenic activity of day 16 bleomycin-treated lung specimens using an in vivo angiogenesis bioassay. Furthermore, when MIP-2 was depleted in vivo by passive immunization, bleomycin-induced pulmonary fibrosis was significantly reduced without a change in the presence of pulmonary neutrophils, fibroblast proliferation, or collagen gene expression. This was also paralleled by a reduction in angiogenesis. These results demonstrate that the angiogenic CXC chemokine, MIP-2, is an important factor that regulates angiogenesis/fibrosis in pulmonary fibrosis.
Similar articles
- IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.
Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. Keane MP, et al. J Immunol. 1999 Nov 15;163(10):5686-92. J Immunol. 1999. PMID: 10553099 - Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury.
Smith RE, Strieter RM, Phan SH, Lukacs NW, Huffnagle GB, Wilke CA, Burdick MD, Lincoln P, Evanoff H, Kunkel SL. Smith RE, et al. J Immunol. 1994 Nov 15;153(10):4704-12. J Immunol. 1994. PMID: 7525712 - VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L. Ou XM, et al. Int Immunopharmacol. 2009 Jan;9(1):70-9. doi: 10.1016/j.intimp.2008.10.002. Epub 2008 Oct 29. Int Immunopharmacol. 2009. PMID: 18976720 - A role for C-C chemokines in fibrotic lung disease.
Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL. Smith RE, et al. J Leukoc Biol. 1995 May;57(5):782-7. doi: 10.1002/jlb.57.5.782. J Leukoc Biol. 1995. PMID: 7539030 Review. - The role of CXC chemokines in pulmonary fibrosis.
Strieter RM, Gomperts BN, Keane MP. Strieter RM, et al. J Clin Invest. 2007 Mar;117(3):549-56. doi: 10.1172/JCI30562. J Clin Invest. 2007. PMID: 17332882 Free PMC article. Review.
Cited by
- Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.
Leonard-Duke J, Agro SMJ, Csordas DJ, Bruce AC, Eggertsen TG, Tavakol TN, Barker TH, Bonham CA, Saucerman JJ, Taite LJ, Peirce SM. Leonard-Duke J, et al. bioRxiv [Preprint]. 2024 Mar 22:2024.03.15.585249. doi: 10.1101/2024.03.15.585249. bioRxiv. 2024. PMID: 38559112 Free PMC article. Preprint. - Pulmonary fibrosis in sarcoidosis.
Asif H, Ribeiro Neto M, Culver D. Asif H, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023027. doi: 10.36141/svdld.v40i3.14830. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 37712364 Free PMC article. - NFATc3 Promotes Pulmonary Inflammation and Fibrosis by Regulating Production of CCL2 and CXCL2 in Macrophages.
Nie Y, Zhai X, Li J, Sun A, Che H, Christman JW, Chai G, Zhao P, Karpurapu M. Nie Y, et al. Aging Dis. 2023 Aug 1;14(4):1441-1457. doi: 10.14336/AD.2022.1202. Aging Dis. 2023. PMID: 37523510 Free PMC article. - Identification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis.
Zhao T, Wu X, Zhao X, Yao K, Li X, Ni J. Zhao T, et al. Front Immunol. 2023 Apr 14;14:1159856. doi: 10.3389/fimmu.2023.1159856. eCollection 2023. Front Immunol. 2023. PMID: 37122736 Free PMC article. - Immune Mechanisms of Pulmonary Fibrosis with Bleomycin.
Ishida Y, Kuninaka Y, Mukaida N, Kondo T. Ishida Y, et al. Int J Mol Sci. 2023 Feb 5;24(4):3149. doi: 10.3390/ijms24043149. Int J Mol Sci. 2023. PMID: 36834561 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical